Melissa M. Hardesty, MD | Authors


Further Research Needed to Improve Outcomes in Advanced Ovarian Cancer

October 04, 2022

Melissa M. Hardesty discusses the key takeaways of the phase 2 OVARIO study of a PARP inhibitor plus a VEGF inhibitor in women with advanced ovarian cancer as well as research still needs to examine in this space.